Abi/P improves outcomes in men with high risk M0 prostate cancer, important findings but still some open questions to discuss Advanced Prostate Cancer Consensus Conference Congrats AttardLab et al! authors.elsevier.com/c/1eIQ0V-4XDTv…

The Lancet AttardLab Nick James also on @Prof-Nick-James.bsky.social Matt Sydes Adding abiraterone to standard hormone therapy did increase severe side-effects. Adding enzalutamide on top of abiraterone and standard therapy did not provide any additional benefit, but did increase side-effects even more.

Well said Nick. A very good time to thank you for all the hard work you do behind the scenes to ensure that the study has been so successful. 🏴󠁧󠁢󠁷󠁬󠁳󠁿 💪 Hope you are able to have a very well deserved break 🇧🇷 Matt Sydes silke gillessen Chris Parker Max Parmar Thank you 🙏

The #STAMPEDE trial is looking for a Clinical Trial Manager - a hugely important post. We look forward to working with the successful candidate as part of our translational projects. Apply before 21st Jan, link in tweet below👇

15 min podcast in conversation with @thelancet on the latest STAMPEDE results plus a commentary on the trial structure, adding arms to trials and broader implications for clinical trials in general thelancet.com/in-conversatio… The ICR MRC Clinical Trials Unit at UCL Cancer Research UK @cancerBRC

1 week to go until our Experts Knowledge Share: 'Targeting Advanced #ProstateCancer with PARP inhibitors: Who, When and Why?' Join the discussion with Drs. Fred Saad, Tanya Dorff Tanya Dorff and Gerhardt Attard AttardLab Book your place here:👉bit.ly/3HGrjIJ

Another important STAMPEDE paper. Tweetorial and link to paper 👇

Thrilled to share our 1st translational study looking at accumulation of copy number alterations & clinical progression in #STAMPEDE (rdcu.be/cUWCv). Thanks to funders Prostate Cancer UK Science and Innovation at Cancer Research UK PCF Science ProstateCancerResearch & Emily Grist for driving this. Tweetorial to come!

It's a #STAMPEDE double bill kicking off the prostate proffered paper session at #ESMO22 with Gert presenting LBA62 and Marina Parry with 1358O. Hope to see you there, Sunday 11th, 8.30am Antibes auditorium.

Interesting genomic data from STAMPEDE particularly M0 patients. Can we avoid abiraterone safely in low genomic but high clinical risk M0 HSPC patients? #ESMO2022 interactions not significant but absolute benefits lower.

Key take homes from STAMPEDE ESMO - Eur. Oncology #ESMO2022 ⭐️More is not always better for AR axis targeting ⭐️GC is interestingly prognostic even in HR PCa ⭐️Predictive biomarkers remain elusive - curious to see Lum A vs Lum B vs basal for AAP effects Well done again to the Team!🦣🦣

Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer: atsv7.wcn.co.uk/search_engine/…

Great all day meeting of the STAMPEDE Translational Research Group. So much great work: imaging, pathology, DNA & RNA profiling, big data mining of NHS data. Big papers pending 😊 ⁦⁦The ICR⁩ ⁦MRC Clinical Trials Unit at UCL⁩ ⁦Science and Innovation at Cancer Research UK⁩ ⁦Prostate Cancer UK⁩ ⁦AttardLab⁩

We’ve updated our website 🚨. More team members, more publications, more news! Check out attardlab.com for our refreshed look.

Today is my last day AttardLab UCL Cancer Institute! I’ve had a brilliant time. Been lucky enough to work with lovely people on interesting projects and have learnt a LOT. I’m excited to join National Cancer Audit Collaborating Centre as senior project manager on newly funded cancer audits rcseng.ac.uk/standards-and-…

Exciting opportunity for computational biologist interested in studying drug resistance in prostate cancer ucl.ac.uk/work-at-ucl/se…

AttardLab is proud to present its latest publication “Copy number architectures define treatment-mediated selection of lethal prostate cancer clones”🎉 in Nature Communications. Kudos to our team for their hard work! 👍 nature.com/articles/s4146…

Find out AttardLab’s latest publication (nature.com/articles/s4146…) showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.

AttardLab’s latest finding (nature.com/articles/s4146…) shows that autosome-defined relationship of metastases in lethal prostate cancer is also characterised by their AR gene architectures.